10 studies found for:    apremilast | Phase 3
Show Display Options
Rank Status Study
1 Active, not recruiting Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: Apremilast 20mg;   Drug: Apremilast 30mg;   Drug: Placebo + 20 mg Apremilast;   Drug: Placebo + 30 mg Apremilast
Phase: Phase 3
Sponsor: Celgene Corporation
Study Start: June 2010
Primary Completion: April 2012
2 Active, not recruiting PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: Apremilast 20mg;   Drug: Apremilast 30mg;   Drug: Placebo + 20 mg Apremilast;   Drug: Placebo + 30 mg Apremilast
Phase: Phase 3
Sponsor: Celgene Corporation
Study Start: September 2010
Primary Completion: July 2012
3 Active, not recruiting PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: Apremilast 20mg;   Drug: Apremilast 30mg;   Drug: Placebo + 20 mg Apremilast;   Drug: Placebo + 30 mg Apremilast
Phase: Phase 3
Sponsor: Celgene Corporation
Study Start: September 2010
Primary Completion: July 2012
4 Active, not recruiting Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
Condition: Psoriatic Arthritis
Interventions: Drug: Apremilast 20mg;   Drug: Apremilast 30mg;   Drug: Placebo + 20mg Apremilast;   Drug: Placebo + 30mg Apremilast
Phase: Phase 3
Sponsor: Celgene Corporation
Study Start: November 2010
Primary Completion: January 2013
5 Active, not recruiting Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
Condition: Plaque Psoriasis
Interventions: Drug: Apremilast;   Drug: Placebo
Phase: Phase 3
Sponsor: Celgene Corporation
Study Start: August 2010
Primary Completion: December 2012
6 Active, not recruiting Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.
Condition: Plaque Psoriasis
Interventions: Drug: Apremilast;   Drug: Placebo
Phase: Phase 3
Sponsor: Celgene Corporation
Study Start: November 2010
Primary Completion: December 2012
7 Active, not recruiting Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
Conditions: Psoriasis;   Psoriatic Arthritis
Interventions: Drug: Apremilast tablet/pill 30 mg;   Drug: Etanercept 50 mg;   Drug: Placebo tablet;   Drug: Placebo injection (saline)
Phase: Phase 3
Sponsor: Celgene Corporation
Study Start: September 2012
Primary Completion: July 2014
8 Active, not recruiting Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis
Condition: Ankylosing Spondyloarthritis
Interventions: Drug: Apremilast tablet 20 mg;   Drug: Apremilast tablet 30 mg BID;   Drug: Placebo
Phase: Phase 3
Sponsor: Celgene Corporation
Study Start: May 2012
Primary Completion: December 2018
9 Recruiting Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: Apremilast 30 mg;   Drug: Placebo
Phase: Phase 3
Sponsor: Celgene Corporation
Study Start: August 2013
Primary Completion: July 2016
10 Completed The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis
Conditions: Sarcoidosis;   Cutaneous Sarcoidosis
Intervention: Drug: CC-100004
Phases: Phase 2 / Phase 3
Sponsor/Collaborators: University of Cincinnati;   Celgene Corporation;   Medical University of South Carolina
Study Start: November 2008
Primary Completion: December 2011

Indicates status has not been verified in more than two years